These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16121704)

  • 1. Technology evaluation: HYB-2055, Hybridon.
    Switaj T; Lasek W
    Curr Opin Mol Ther; 2005 Aug; 7(4):376-83. PubMed ID: 16121704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technology evaluation: GEM-231, Hybridon.
    Yeung PK
    Curr Opin Mol Ther; 2003 Jun; 5(3):315-20. PubMed ID: 12870443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
    Tamm I
    Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology evaluation: CpG-7909, Coley.
    Paul S
    Curr Opin Mol Ther; 2003 Oct; 5(5):553-9. PubMed ID: 14601526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology evaluation: SB-485232, GlaxoSmithKline.
    Golab J; Stoklosa T
    Curr Opin Mol Ther; 2005 Feb; 7(1):85-93. PubMed ID: 15732534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technology evaluation: rh lactoferrin, Agennix.
    Andersen JH
    Curr Opin Mol Ther; 2004 Jun; 6(3):344-9. PubMed ID: 15264438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience.
    Spicer J
    Curr Opin Mol Ther; 2005 Apr; 7(2):182-91. PubMed ID: 15844627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology evaluation: HSPPC-96, antigenics.
    Minev BR
    Curr Opin Mol Ther; 2003 Dec; 5(6):680-7. PubMed ID: 14755896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer.
    Sachdev D
    Curr Opin Mol Ther; 2007 Jun; 9(3):299-304. PubMed ID: 17608029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technology evaluation: Rexin-G, Epeius Biotechnologies.
    Morse M
    Curr Opin Mol Ther; 2005 Apr; 7(2):164-9. PubMed ID: 15844625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.
    LaCasce AS; Freedman AS
    Semin Hematol; 2008 Apr; 45(2):85-9. PubMed ID: 18381102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technology evaluation: Onyvax-P, Onyvax.
    Doehn C; Böhmer T; Jocham D
    Curr Opin Mol Ther; 2005 Oct; 7(5):511-9. PubMed ID: 16248287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technology evaluation: PK1, Pfizer/Cancer Research UK.
    Bilim V
    Curr Opin Mol Ther; 2003 Jun; 5(3):326-30. PubMed ID: 12870445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug evaluation: ProCord - a potential cell-based therapy for spinal cord injury.
    Kigerl K; Popovich P
    IDrugs; 2006 May; 9(5):354-60. PubMed ID: 16676272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptors--novel targets in allergic airway disease (probiotics, friends and relatives).
    Feleszko W; Jaworska J; Hamelmann E
    Eur J Pharmacol; 2006 Mar; 533(1-3):308-18. PubMed ID: 16436277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.
    Burnett JR
    Curr Opin Mol Ther; 2006 Oct; 8(5):461-7. PubMed ID: 17078389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of toll-like receptor therapeutics.
    Parkinson T
    Curr Opin Mol Ther; 2008 Feb; 10(1):21-31. PubMed ID: 18228178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda.
    Vulfovich M; Saba N
    Curr Opin Mol Ther; 2005 Oct; 7(5):502-10. PubMed ID: 16248286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technology evaluation: AVI-4126, AVI BioPharma.
    Stephens AC
    Curr Opin Mol Ther; 2004 Oct; 6(5):551-8. PubMed ID: 15537057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of biologic response modifiers in infectious disease.
    Masihi KN; Schäfer H
    Infect Dis Clin North Am; 2011 Dec; 25(4):723-31. PubMed ID: 22054752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.